Gracell Acquires CLDN18.2 Antibodies for CAR-T Candidates
publication date: Aug 16, 2021
Gracell Bio, a Suzhou CAR-T company, acquired rights to FutureGen's CLDN18.2 antibodies, which it will use to develop novel immune cell therapies for solid tumors. CLDN18.2 is a tumor biomarker that is overexpressed in a variety of tumors, including gastric or gastroesophageal junction cancers, pancreatic cancers and esophageal cancers. Gracell is developing several technologies to improve the efficacy and lower the cost of CAR-T therapies. It will make upfront, milestone and royalty payments to Palo Alto's FutureGen. More details....
Stock Symbols: (NSDQ: GRCL)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.